1 published article · Updated continuously
11 trials tracked for Diverticulitis: 6 in phase 3 or 4 and 1 with published results. The most-cited published study has 36 citations.
Showing the 11 most-cited and recently-updated of 11 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Tigecycline has demonstrated clinical efficacy in the treatment of diverticulitis. In a study of 467 patients, tigecycline showed significant improvements in both clinically evaluable and microbiologically evaluable patients achieving a clinical response of cure at the test-of-cure visit (p=0.009 and p=0.020 respectively) 4. Another trial involving 473 patients confirmed a statistically significant difference in microbiologically evaluable patients with a clinical response of cure at the test-of-cure visit (p=0.001) 3. However, tigecycline did not significantly impact the number of days of inpatient healthcare resource utilization prior to the test-of-cure visit (p=0.750) 3.
Research into recurrence prevention shows mixed results for SPD476. A phase 3 trial of 590 patients found a statistically significant difference in the percentage of subjects without recurrence of diverticulitis (p=0.047), though the percentage of subjects who were CT-recurrence free did not reach statistical significance (p=0.063) 5. In a subsequent phase 3 trial involving 592 patients, the use of SPD476 in combination with MMX™ mesalazine showed no statistically significant difference in the percentage of subjects without recurrence (p=0.778) or those who were CT-recurrence free (p=0.685) 6.
Other interventions evaluated for diverticulitis include Bupivacaine 1 and a Compression Anastomosis Device 2.
AI synthesis of 11 cited trials, updated Aug 4, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
